Tuesday, 9 July 2013

Recent Report: Pharmaceutical Industry In China Q2 2013

Pharmaceutical Industry in China - An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges” provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 196 tables & figures within 142 pages. The Chinese biopharmaceutical market is presented as follows:

To Read The Complete Report with  TOC :-

·         By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)

A wealth of financial information is provided including:

·         Company financials, sales & revenue figures historical to Q2 2013
·         China GDP, economic growth, export (bulk drug, formulations) figures
·         Indian health expenditure as a function of GDP
·         Growth change figures of emerging and developing countries (India, Russia, China, Brazil)
·         Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)
·         Projected figures of strategic emerging industry GDP percentage contribution

SWOT, Economic and Business Environment specifics include:

·         Key strengths, weaknesses and threats influencing leading player position within the market
·         Top Five Contract Pharmaceutical Export Markets of China
·         Major players within China’s leading therapeutic markets (e.g., cancer, allergy, liver disease)
·         Multinational penetration into the Chinese Pharma Market
·         Comprehensive product portfolios, R&D activity and pipeline therapeutics 
·         M&A activity and future strategies of top Chinese pharmacos
·         Economic indicators, trade policy, merchandise and commercial trade statistics
·         Gross Domestic Product of China, historic and projection analysis
·         Chinese economic outlook in comparison to advanced economies 
·         Three Tier ‘Pharmerging’ Markets with Potential for Significant Growth 
·         Prescription drug sales distribution channels in China
·          Major biogeneric products in China

Forecast projections and future growth rates are provided to give you a forthcoming perspective of this growing industry. Current developments relating to patent expirations, government funding, and regulations are discussed.  The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed. 

What you will gain:

·         An in-depth understanding of the Chinese biopharmaceutical market and it’s environment
·         Current market facts, figures and product lines of key players in the industry
·         An insight into how generic therapeutics will propagate the Chinese biopharmaceutical market
·         Knowledge of how the Chinese biopharma market will integrate into the global healthcare market 
·         Information on key regulatory and government policies 
·         Data on levels of private and publically funded biopharma studies in China
·         Strategies on how to adapt and restructure current business models to this industry

To Buy a Copy Of This Report:-

This report tackles key concerns to the Chinese biopharmaceutical market such as:

·         Lack of regulatory policy and legislation 
·         Reimbursement schemes and payers concerns
·         Funding and government sponsorship issues
·         International scepticism of Chinese safety and efficacy therapeutic profiles
This report will tell you if the companies mentioned are:

·         Strong, competitive players
·         Pooling their resources for specific growth and therapeutic areas
·         Investing strategically in R&D
·         Have a history of strategic M&A activity

M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948

No comments:

Post a Comment